Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

The role of the acute octreotide suppression test in detecting patients with neuroendocrine neoplasms (CROSBI ID 264361)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Kruljac, Ivan ; Vičić, Ivan ; Blaslov, Kristina ; Kolak, Zorica ; Benković, Martina ; Kust, Davor ; Ladika Davidović, Blaženka ; Tometić, Gordan ; Penavić, Ivan ; Dabelić, Nina et al. The role of the acute octreotide suppression test in detecting patients with neuroendocrine neoplasms // Neuroendocrinology, 107 (2018), 3; 284-291. doi: 10.1159/000492934. Epub 2018 Aug 16.

Podaci o odgovornosti

Kruljac, Ivan ; Vičić, Ivan ; Blaslov, Kristina ; Kolak, Zorica ; Benković, Martina ; Kust, Davor ; Ladika Davidović, Blaženka ; Tometić, Gordan ; Penavić, Ivan ; Dabelić, Nina ; Vazdar, Ljubica ; Pavić, Tajana ; Vrkljan, Milan

engleski

The role of the acute octreotide suppression test in detecting patients with neuroendocrine neoplasms

BACKGROUND: Serum chromogranin A (CgA) is routinely used as a biomarker in patients with neuroendocrine neoplasms (NENs). Several conditions and comorbidities may be associated with falsely elevated CgA, often leading to extensive diagnostic evaluation, which may be costly and harmful. The aim of this study was to analyze the effectiveness of the acute octreotide suppression test (AOST) in differentiating falsely elevated serum CgA. METHODS: Our prospective study enrolled 45 patients from two different patient cohorts: (1) 29 patients with suspicion or presence of NENs (extensive workup and subsequent biopsy confirmed 16 NENs) ; (2) 16 consecutive patients admitted via the Emergency Department without NENs (non- NENs). AOST was performed after an overnight fast. Baseline CgA was measured, after which 0.25 mg of octreotide was administered subcutaneously. CgA was measured 3 and 6 h after administration. RESULTS: Baseline CgA levels were similar in NENs and non-NENs. At the end of the AOST, CgA decreased by a median of 83.3% (41.0- 127.4) in non-NENs and 13.8% (0.0-43.6) in NENs (p < 0.001). In patients with increased baseline CgA, a decrease in CgA at the 6th hour of < 51.3% had 90.0% sensitivity and 88.9% specificity in detecting NENs. In patients with normal baseline serum CgA, a decrease in CgA at the 3rd hour of < 17.6% had 83.3% sensitivity and 81.8% specificity in detecting patients with NENs. The diagnostic accuracy of the AOST in the entire study population was 86.7%. CONCLUSIONS: AOST is a promising tool to increase the diagnostic accuracy of serum CgA.

Chromogranin A ; Diagnosis ; Neuroendocrine neoplasm ; Octreotide suppression test

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

107 (3)

2018.

284-291

objavljeno

0028-3835

1423-0194

10.1159/000492934. Epub 2018 Aug 16.

Povezanost rada

Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje), Kliničke medicinske znanosti

Poveznice
Indeksiranost